PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
Simple Summary
Collet, L.; Péron, J.; Penault-Llorca, F.; Pujol, P.; Lopez, J.; Freyer, G.; You, B. PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers 2022, 14, 599. https://doi.org/10.3390/cancers14030599
Collet L, Péron J, Penault-Llorca F, Pujol P, Lopez J, Freyer G, You B. PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers. 2022; 14(3):599. https://doi.org/10.3390/cancers14030599
Chicago/Turabian StyleCollet, Laetitia, Julien Péron, Frédérique Penault-Llorca, Pascal Pujol, Jonathan Lopez, Gilles Freyer, and Benoît You. 2022. "PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers" Cancers 14, no. 3: 599. https://doi.org/10.3390/cancers14030599